HDAX Therapeutics
HDAX Therapeutics is a preclinical stage company developing next-gen (2-site binding) small molecule therapeutics for diseases stemming from microtubule dysfunction.
Sites: CDL-Oxford, CDL-Toronto, CDL-Vancouver, CDL-Wisconsin
Cohort Year: 2023/24
Stream: Advanced Therapies
HDAX Therapeutics is a preclinical stage company developing next-gen (2-site binding) small molecule therapeutics for diseases stemming from microtubule dysfunction.